Discontinued — last reported Q1 '26
EBIT at other companies
Other financials
Where this comes from
Calculated from Tango Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's EBIT?
- Tango Therapeutics (TNGX) reported EBIT of -$48.77M in Q1 2026.
- How has Tango Therapeutics's EBIT changed year-over-year?
- Tango Therapeutics's EBIT decreased by 14.7% year-over-year, from -$42.53M to -$48.77M.
- What is the long-term trend for Tango Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Tango Therapeutics's EBIT has grown at a 27.1% compound annual growth rate (CAGR), from -$42.59M to -$111.29M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.